Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome

被引:165
作者
Konishi, Tsuyoshi [1 ,2 ]
Shimada, Yoshifumi [1 ,3 ]
Hsu, Meier [4 ]
Tufts, Lauren [1 ]
Jimenez-Rodriguez, Rosa [1 ]
Cercek, Andrea [5 ]
Yaeger, Rona [5 ]
Saltz, Leonard [5 ]
Smith, J. Joshua [1 ]
Nash, Garrett M. [1 ]
Guillem, Jose G. [1 ]
Paty, Philip B. [1 ]
Garcia-Aguilar, Julio [1 ]
Gonen, Mithat [4 ]
Weiser, Martin R. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA
[2] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[3] Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, Niigata, Japan
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
COLORECTAL-CANCER; TUMOR-MARKERS; PROGNOSTIC-SIGNIFICANCE; CURATIVE RESECTION; FOLLOW-UP; CEA; LEVEL; STAGE; RECURRENCE; METASTASES;
D O I
10.1001/jamaoncol.2017.4420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Guidelines recommend measuring preoperative carcinoembryonic antigen (CEA) in patients with colon cancer. Although persistently elevated CEA after surgery has been associated with increased risk formetastatic disease, prognostic significance of elevated preoperative CEA that normalized after resection is unknown. OBJECTIVE To investigate whether patients with elevated preoperative CEA that normalizes after colon cancer resection have a higher risk of recurrence than patients with normal preoperative CEA. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort analysiswas conducted at a comprehensive cancer center. Consecutive patients with colon cancer who underwent curative resection for stage I to III colon adenocarcinoma at the center from January 2007 to December 2014 were identified. EXPOSURES Patients were grouped into 3 cohorts: normal preoperative CEA, elevated preoperative but normalized postoperative CEA, and elevated preoperative and postoperative CEA. MAIN OUTCOMES AND MEASURES Three-year recurrence-free survival (RFS) and hazard function curves over time were analyzed. RESULTS A total of 1027 patients (461 [50.4%] male; median [IQR] age, 64 [53-75] years) were identified. Patients with normal preoperative CEA had 7.4% higher 3-year RFS (n = 715 [89.7%]) than the combined cohorts with elevated preoperative CEA (n = 312 [82.3%]) (P =.01) but had RFS similar to that of patients with normalized postoperative CEA (n = 142 [87.9%]) (P =.86). Patients with elevated postoperative CEA had 14.9% lower RFS (n = 57 [74.5%]) than the combined cohorts with normal postoperative CEA (n = 857 [89.4%]) (P =.001). The hazard function of recurrence for elevated postoperative CEA peaked earlier than for the other cohorts. Multivariate analyses confirmed that elevated postoperative CEA (hazard ratio [HR], 2.0; 95% CI, 1.1-3.5), but not normalized postoperative CEA (HR, 0.77; 95% CI, 0.45-1.30), was independently associated with shorter RFS. CONCLUSIONS AND RELEVANCE Elevated preoperative CEA that normalizes after resection is not an indicator of poor prognosis. Routine measurement of postoperative, rather than preoperative, CEA is warranted. Patients with elevated postoperative CEA are at increased risk for recurrence, especially within the first 12 months after surgery.
引用
收藏
页码:309 / 315
页数:7
相关论文
共 30 条
  • [1] Bast RC, 1996, J CLIN ONCOL, V14, P2843
  • [2] Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study
    Bertelsen, Claus Anders
    Neuenschwander, Anders Ulrich
    Jansen, Jens Erik
    Wilhelmsen, Michael
    Kirkegaard-Klitbo, Anders
    Tenma, Jutaka Reilin
    Bols, Birgitte
    Ingeholm, Peter
    Rasmussen, Leif Ahrenst
    Jepsen, Lars Vedel
    Iversen, Else Refsgaard
    Kristensen, Bent
    Gogenur, Ismail
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 161 - 168
  • [3] Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen, CC
    Yang, SH
    Lin, JK
    Lin, TC
    Chen, WS
    Jiang, JK
    Wang, HS
    Chang, SC
    [J]. JOURNAL OF SURGICAL RESEARCH, 2005, 124 (02) : 169 - 174
  • [4] Choi Jin Sub, 1997, Yonsei Medical Journal, V38, P1
  • [5] CHU DZJ, 1991, ARCH SURG-CHICAGO, V126, P314
  • [6] Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
    Duffy, M. J.
    van Dalen, A.
    Haglund, C.
    Hansson, L.
    Holinski-Feder, E.
    Klapdor, R.
    Lamerz, R.
    Peltomaki, P.
    Sturgeon, C.
    Topolcan, O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (09) : 1348 - 1360
  • [7] DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES
    GOLD, P
    FREEDMAN, SO
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) : 439 - +
  • [8] SPECIFIC CARCINOEMBRYONIC ANTIGENS OF HUMAN DIGESTIVE SYSTEM
    GOLD, P
    FREEDMAN, SO
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 122 (03) : 467 - &
  • [9] Hess KR, 1999, STAT MED, V18, P3075, DOI 10.1002/(SICI)1097-0258(19991130)18:22<3075::AID-SIM244>3.0.CO
  • [10] 2-6